Internal restructuring
Southern and Eastern; South-West (IRL);
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

100 jobs
Number of planned job losses
Job loss
Announcement Date
20 February 2008
Employment effect (start)
Foreseen end date


Glaxosmithkline, the pharmaceutical firm, is to reduce its workforce at Currabinny, Co Cork, by 100. The company said that due to falling sales for a number of the products produced at Cork there was “excess capacity at Currabinny, and this situation is not sustainable”. The Currabinny site produces ingredients for a number of drugs, including Tykerb, which is used in the treatment of breast cancer. Some 500 people are employed there. Finbar Whyte, the site director, said the redundancies were not a reflection on the performance of the site or the commitment of the employees. “Unfortunately, due to falling volumes globally of some of our site's products, we have excess capacity at Currabinny, and this situation is not sustainable”, he said.


  • 22 February 2008: The Irish Times
  • 21 February 2008: The Irish Times


Eurofound (2008), Glaxo Smith Kline, Internal restructuring in Ireland, factsheet number 66335, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/66335.